AbCellera vs Restream

Side-by-side comparison of AI visibility scores, market position, and capabilities

AbCellera leads in AI visibility (38 vs 23)
AbCellera logo

AbCellera

GrowthLife Sciences & BioTech

Antibody Discovery

Vancouver-based antibody discovery platform with 104+ partner programs; $75M FY2025 revenue. Expanding into wholly owned assets with ABCL635 in Phase 1 for vasomotor symptoms.

AI VisibilityBeta
Overall Score
D38
Category Rank
#1 of 1
AI Consensus
68%
Trend
up
Per Platform
ChatGPT
31
Perplexity
39
Gemini
34

About

AbCellera Biologics was founded in 2012 in Vancouver, Canada by Carl Hansen, growing out of research at the University of British Columbia. The company built a high-throughput antibody discovery platform integrating microfluidics, genomics, single-cell sequencing, and AI/ML to rapidly identify therapeutic antibody candidates from natural immune responses. AbCellera played a prominent role in the COVID-19 pandemic by discovering bamlanivimab for Eli Lilly in under 90 days.\n\nAbCellera's partnership model operates on a discovery fee plus downstream milestone and royalty structure, having started over 104 partner-initiated programs with downstream participation as of December 2025. Partners include major pharmaceutical companies and biotechs; the company expanded its collaboration with AbbVie in 2025 to develop T-cell engagers for oncology. Total FY2025 revenue was $75 million ($47M from royalties/licensing, $27M from partnered program work), compared to $29 million in 2024—a dramatic increase driven by royalty flows from approved medicines.\n\nIn 2025 AbCellera began transitioning from pure partnership model toward wholly owned therapeutic assets, with ABCL635 (a GnRH receptor antibody for vasomotor symptoms) entering Phase 1. The company maintains approximately $700 million in liquidity, providing a long runway. AbCellera is considered a foundational infrastructure provider for the antibody-based drug discovery ecosystem.

Full profile
Restream logo

Restream

GrowthCreator Economy

Multi-Platform Live Streaming

Austin multi-streaming platform broadcasting live video to 30+ destinations including Twitch, YouTube, and Facebook Live simultaneously; trusted by creators, media companies, and businesses.

AI VisibilityBeta
Overall Score
D23
Category Rank
#1 of 1
AI Consensus
52%
Trend
up
Per Platform
ChatGPT
33
Perplexity
22
Gemini
31

About

Restream is an Austin-based live streaming company that provides multi-stream broadcasting technology enabling content creators, businesses, and media companies to broadcast live video simultaneously to over 30 streaming destinations including Twitch, YouTube, Facebook Live, LinkedIn Live, and custom RTMP destinations from a single source. The platform eliminates the need to choose a single streaming platform by enabling simultaneous multi-destination broadcasting, maximizing audience reach across wherever viewers are watching. Restream also provides a browser-based live studio for creating professional broadcasts without dedicated streaming hardware, including overlays, lower-thirds, guest invitations, and screen sharing. The company serves a broad range of users from gaming streamers and podcasters to corporate communications teams running product launches and all-hands meetings. Founded in 2015 in Kyiv with operations in Austin, Restream has grown to serve millions of streamers globally. The company raised over $50M from investors including Bessemer Venture Partners and competes with StreamYard, OBS, and Wirecast in the live streaming software market.

Full profile

AI Visibility Head-to-Head

38
Overall Score
23
#1
Category Rank
#1
68
AI Consensus
52
up
Trend
up
31
ChatGPT
33
39
Perplexity
22
34
Gemini
31
45
Claude
14
39
Grok
30

Key Details

Category
Antibody Discovery
Multi-Platform Live Streaming
Tier
Growth
Growth
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only AbCellera
Antibody Discovery
Only Restream
Multi-Platform Live Streaming

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.